Methyl 2-bromomethyl-3-nitrobenzoate:Exports & Compliance White Paper 2026

I. Executive Summary

Methyl 2-(bromomethyl)-3-nitrobenzoate, CAS 98475-07-1, is a benzylic bromide used as a difunctional electrophilic building block in pharmaceutical synthesis, most prominently in the production of the immunomodulatory imide drug class in which the methyl benzoate serves as the aromatic partner that is joined to an aminoglutarimide unit before nitro reduction closes the isoindolinone. Its molecular formula C9H8BrNO4 and molar mass near 274 grams per mol conceal a demanding dual identity: it is simultaneously a productive alkylating reagent and a genotoxic hazard that finished-drug makers must control to trace limits in their own products.

That duality governs the entire commercial relationship. A buyer purchasing several kilograms is not simply buying assay and delivery; the buyer is buying evidence that assay, related nitroaromatic isomers, free bromide, residual solvents and thermal stability have been characterised by validated methods, that the chosen acceptable-intake reasoning has been documented, and that the material will arrive without having decomposed. Consequently this is a CDMO product rather than a catalogue product, transacted through technology-transfer discussions, confidentiality agreements and stability commitments.

The commercial centre of gravity has shifted decisively toward Asia, where Chinese and Indian custom-synthesis organisations supply both non-GMP and GMP campaign material, while European and North American buyers control specifications, hold reference-standard programmes and audit remotely. Supply to non-qualified counterparties is constrained by know-your-customer review and end-use declaration, because the molecule is a potent alkylating agent whose mishandling creates genuine occupational hazard.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule combines three features in one small aromatic frame: an ortho-bromomethyl substituent, an adjacent nitro group and a methyl ester. Each contributes differently. The ester moderates ring electronics and provides a handle for later hydrolysis chemistry; the nitro group withdraws electron density and stabilises the benzylic position against simple displacement while activating the ring toward certain substitution patterns; and the benzylic carbon bearing bromide is the single most reactive site, primed for nucleophilic attack by amines, imides and related nucleophiles.

• Benzylic bromide as an electrophilic alkylating centre: The carbon-bromine bond is highly polarisable and the resulting benzylic transition state is stabilised by the ring, so the compound alkylates nitrogen, sulfur and oxygen nucleophiles efficiently. That same reactivity is why it is treated as an alerting structure in mutagenicity assessment and why both the supplier and the customer must define occupational exposure bands and handling envelopes before a single container is opened.
• Lachrymatory and corrosive behaviour with limited thermal headroom: Benzylic bromides are potent lachrymators with skin and eye corrosion potential, and this material additionally decomposes exothermically once its decomposition onset is exceeded, liberating hydrogen bromide. It is therefore subjected to differential scanning calorimetry and adiabatic calorimetry screening before scale-up, and those results set drying temperatures, distillation policy and storage limits rather than being filed merely for regulatory appearance.

2.2 Synthesis and Manufacturing Technologies

Only route class and purification strategy are discussed here. Industrial supply rests on aromatic nitration and side-chain radical halogenation concepts, applied to a methyl benzoate precursor, and executed in equipment designed for corrosive halogen chemistry.

• Nitration followed by regioselective side-chain bromination: The dominant approach nitrates a methyl toluate precursor to install the nitro group with the required regiochemistry, then brominates the benzylic methyl group selectively. The critical quality issue is regiochemical fidelity: incomplete bromination leaves the methyl analogue, over-bromination produces dibromomethyl species, and imperfect nitration control generates positional nitro isomers, each of which behaves differently downstream and must therefore be resolved analytically.
• Halide displacement from the corresponding acid or alcohol, with crystallisation polishing: Where the corresponding benzyl alcohol or benzoic acid is available, conversion to the bromide followed by ester control offers an alternative sequence. Regardless of route, final purification is achieved through controlled crystallisation under inert atmosphere at low temperature, because distillation is discouraged for thermally sensitive benzylic bromides and because crystallisation removes both isomeric and inorganic bromide burden.

2.3 Core Application Matrix

• Alkylating building block for imide-class APIs: Installation of an aminoglutarimide fragment onto the benzylic carbon, followed by nitro reduction and ring closure, produces the isoindolinone framework used in lenalidomide-type immunomodulatory substances, making this the highest-value and most specification-sensitive outlet.
• Reference and analytical standard supply: Certified material supports genotoxic-impurity method development, limit-method validation, system suitability and purge-factor studies in finished-drug quality control laboratories.
• Custom heterocyclic synthesis and route scouting: Used in discovery and development programs where a nitroaromatic benzylic electrophile is needed to explore structure-activity relationships under research-use-only conditions.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand tracks generic entry into the immunomodulatory imide class and its successor molecules. As originator exclusivity unwinds in successive territories, multiple generic filings each require their own supplier qualification campaign, generating lumpy but predictable requirements for both commercial-intermediate and reference-standard material. Parallel demand arises from ICH M7 implementation itself: every finished-drug manufacturer seeking approval must demonstrate control of this genotoxic intermediate in its own product, and that obligation sustains a steady market for analytical quantities that is largely insensitive to API volume.

3.2 Capacity Distribution and Export Flows

Capacity is not expressed as nameplate amines or fine-chemical tonnage but as available high-containment suites and skilled development chemists. Chinese custom-synthesis organisations in Jiangsu, Shandong, Zhejiang and Sichuan dominate provision of development-scale and early commercial quantities, supported by dense aromatic nitration and halogenation infrastructure. Indian CDMOs centred on Hyderabad, Bengaluru, Ankleshwar and Vapi increasingly supply GMP campaigns with strong documentation. European producers in Germany, Switzerland, Italy and Spain retain smaller, high-containment capacity serving buyers who require regional manufacture, short communication lines and auditability.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is best understood in three tiers. The lowest is research-use-only material sold in gram to kilogram quantities for discovery work, priced mainly on development effort. The middle tier is non-GMP but fully characterised commercial intermediate. The highest is GMP campaign material made under ICH Q7 with starting-material controls, validated methods and audit access, carrying a multiple of the middle tier. A distinct fourth segment is certified reference material where traceability rather than kilograms defines value.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Two regulatory regimes apply at once and they pull in different directions. As a hazardous electrophilic substance in its own right, the compound is governed by chemical law: registration, classification, labelling, transport and occupational exposure. As a potential impurity in a medicine, it is governed through a customer's marketing authorisation, against a compound-specific acceptable intake justified by genotoxicity reasoning.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and CLP hazard communication: Import into the European Union above one tonne per year requires registration supported by data addressing mutagenicity, skin corrosion and eye damage, with classification and labelling and exposure scenario development for industrial intermediates and laboratory use. Importers must also observe restrictions relevant to the substance itself and to solvents used in its manufacture. Because registrations are costly relative to the low volumes typically involved, buyers should confirm whether their supplier holds its own registration or relies on an Only Representative.
• Relationship with downstream marketing authorisations: Where the material enters a regulated supply chain, European customers expect starting-material definition consistent with ICH Q11, ICH Q7 control and ICH Q3D elemental-impurity risk assessment, plus change-control commitments. They also scrutinise solvent selection against restrictions and any regional expectations for N-methylpyrrolidone and halogenated solvents that may have been used upstream.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory, EPA frameworks and brominated waste: Material imported into the United States must be on the TSCA inventory or covered by an applicable exemption, with importer certification under the TSCA import rule. Environmental permitting governs brominated waste destruction and hydrogen bromide scrubbing, and occupational exposure must be managed through written hazard communication, engineering controls and personal protective equipment appropriate to a lachrymatory corrosive.
• ICH M7 acceptable-intake reasoning and FDA expectations: Buyers must present this compound as a mutagenic impurity with a documented control strategy: an Ames-test result or robust structure-activity assessment placing it within ICH M7 thinking, a compound-specific acceptable intake derived either from carcinogenicity data or from the threshold-of-toxicological-concern concept at 1.5 micrograms per day, with less-than-lifetime adjustment justified by treatment duration, and analytical evidence that purge brings the finished substance below that limit.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Sustainability pressure here is specific rather than generic. Brominated chemistry raises questions about halogenated emissions, solvent choice and waste destruction efficiency, while customers increasingly ask their intermediate suppliers to account for process mass intensity and to demonstrate that halogenated effluent does not reach water courses.

5.1 Carbon Footprint and Circular Economy

Because annual volumes are modest, absolute emissions are small, but energy intensity per kilogram is high once cryogenic cooling, enclosed handling, dedicated ventilation and off-gas treatment are counted. The practical levers are therefore solvent selection and recovery, replacement of halogenated solvents with less problematic alternatives where chemistry permits, and heat integration around low-temperature operations. Buyers increasingly accept a simple, honest statement of these measures in preference to unqualified offset claims, and several Asian sites have added renewable electricity supply and high-efficiency refrigeration specifically to remain competitive in European tenders.

5.2 Sustainable Sourcing and Traceability

Traceability obligations concentrate on provenance and containment rather than on bio-based content. Customers require documented starting-material sources, a change-control agreement covering any modification to route, solvent or site, and disclosure of subcontracted steps. They also require assurance that brominated waste is routed to permitted destruction with documented destruction efficiency, and that hydrogen bromide releases are scrubbed. Where reference material is supplied, ISO 17034 production and ISO 17025 calibration competence are increasingly requested, and a transparency package covering business ethics and labour practice is standard among multinational buyers.

VI. Supply Chain Resilience and Export Logistics

Logistics determines specification survival. A benzylic bromide that spends a week in an unrefrigerated container at a hot port arrives as a different material from the one released, typically with lower assay, higher free bromide and visible colour, and disputes of that kind are notoriously hard to resolve after customs release.

6.1 Packaging Standards and Moisture/Contamination Control

• Amber glass or lined containers under inert headspace: Small quantities are packed in amber glass bottles with polytetrafluoroethylene-lined closures, larger quantities in lined steel or high-density polyethylene drums, with nitrogen headspace and desiccant. Light exclusion, moisture exclusion and oxygen exclusion each serve a distinct purpose: preventing radical-side reactions, hydrolysis and oxidative discolouration respectively.
• Dedicated containment and cleaning discipline: Production and packing are performed in enclosed suites with local exhaust and scrubbing, using dedicated or rigorously cleaned contact parts validated for residue removal. Because the compound is both corrosive and lachrymatory, transfer operations are designed to avoid any open handling, and operators work under a defined occupational exposure band with health-based exposure limits documented before campaign start.

6.2 Dangerous Goods Identification and Transit Protocols

Benzylic bromides of this type are normally offered as Class 8 corrosive solids, most often under UN 3261 for corrosive solid, acidic, organic, not otherwise specified, or under the corresponding corrosive-liquid entry where material is supplied molten or in solution; however each shipment must be classified against the specific supplier data and Section 14 of its own safety data sheet. Practical protocol is refrigerated despatch at two to eight degrees Celsius with passive cooling and continuous temperature logging, summer route planning that avoids prolonged yard exposure, pre-alert despatch notification to the consignee's quality unit, and mandatory know-your-customer review before release to any new counterparty.

VII. Enterprise Global Expansion Strategy Guide

Suppliers succeed here by selling discipline and evidence rather than kilograms, because their customers are typically quality and regulatory functions inside finished-drug organisations.

1. Offer a graded campaign model: Structure supply as development-grade, non-GMP characterised and GMP campaign material with defined entry and exit points, so that a customer can begin method development cheaply and later transfer into documented supply without re-inventing the route.
2. Own the impurity argument: Provide a ready package covering ICH M7 classification reasoning, acceptable-intake derivation including less-than-lifetime justification where claimed, validated limit-method references, purge-factor support and, where applicable, ISO 17034 reference material so that the customer's dossier can be assembled quickly.
3. Demonstrate containment competence: Publish thermal-stability screening outcomes, occupational-exposure-band assignment with health-based exposure limits, request-based end-use declarations and documented refusal of non-qualified counterparties, together with dual-site capability that insulates customers from single-plant disruption.

VIII. Conclusion

Methyl 2-(bromomethyl)-3-nitrobenzoate is a small intermediate carrying disproportionate regulatory weight. Every difficulty in supplying it, from the genotoxic acceptable-intake argument to robust packaging and refrigerated transit, flows from that same reactive centre, which rewards suppliers who design their offer around evidence rather than tonnage.

Requirements should grow as immunomodulatory imide generic competition broadens and as inspectors expect more rigorous purge justifications for alerting impurities. Organisations combining route-class expertise, validated analytics, occupational containment and honest end-use screening will remain preferred partners, while those treating the compound as an ordinary catalogue item will be excluded from regulated supply chains.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Methyl 2-(bromomethyl)-3-nitrobenzoate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Methyl 2-(bromomethyl)-3-nitrobenzoate supply chain:

• China (Jiangsu, Shandong, Zhejiang and Sichuan custom synthesis belt): Chinese CDMOs dominate development-scale and early commercial volumes, drawing on dense nitration and halogenation infrastructure, in-house analytical capability and fast quotation cycles. The strongest operators now offer full non-GMP to GMP progression, English-language documentation and remote audit readiness, which together make them practical partners for both originator and generic programmes.
• India (Hyderabad, Bengaluru, Ankleshwar and Vapi CDMO cluster): Indian partners are strongest in regulated-market documentation and audit culture, with high-containment suites, established starting-material controls and experience defending ICH M7 arguments in customer filings. They are frequently selected where the campaign must eventually be described in a marketing authorisation.
• Europe (Germany, Switzerland, Italy and Spain fine chemicals network): European suppliers hold smaller but very highly contained capacity, valued by buyers needing regional manufacture, short logistics chains, ISO 17034 reference material and face-to-face technical dialogue. Specialist distributors additionally serve the analytical-standard segment where grams rather than kilograms define commercial value.